Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease, as well as to treat chronic kidney disease-associated with pruritus. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation; and Rutgers to develop and commercialize products incorporating nalbuphine for any human or animal use. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.
IPO Year: 2019
Exchange: NASDAQ
Website: trevitherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/12/2024 | $6.00 → $7.50 | Buy | H.C. Wainwright |
| 9/9/2024 | $6.00 → $7.00 | Outperform | Leerink Partners |
| 8/30/2024 | $6.00 | Buy | H.C. Wainwright |
| 8/30/2024 | $9.00 | Outperform | Raymond James |
| 6/13/2024 | $7.00 | Buy | Rodman & Renshaw |
| 4/12/2023 | $6.00 | Buy | B. Riley Securities |
| 11/22/2022 | $6.00 | Outperform | SVB Leerink |
| 11/11/2021 | $10.00 → $8.00 | Buy | Needham |
| 8/13/2021 | $12.00 → $10.00 | Buy | Needham |
SCHEDULE 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
424B5 - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
10-Q - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
8-K - Trevi Therapeutics, Inc. (0001563880) (Filer)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13D/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
SC 13G/A - Trevi Therapeutics, Inc. (0001563880) (Subject)
NEW HAVEN, Conn., Jan. 30, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor conferences in February. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)">
Last patient completed the Phase 2a RIVER trial in refractory chronic cough (RCC) in early January and topline results continue to be expected in the first quarter of 2025 Approximately 80% of enrollment complete in the Phase 2b CORAL trial in idiopathic pulmonary fibrosis (IPF) patients with chronic cough and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Jan. 8, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC),
NEW HAVEN, Conn., Dec. 16, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy, Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the pricing of an underwritten offering of 12,500,000 shares of its common stock at a price to investors of $4.00 per share, for total proceeds of $50 million, before deducting underwriting discounts and commissions and expenses payable by Trevi. All of the shares in the offering are being sold by Trevi. The offering is expected to close on December 17, 2024, subject to
Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the positive outcome from the planned sample size re-estimation (SSRE) for the ongoing Phase 2b CORAL trial in IPF patients with chronic cough, w
Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:00 p.m. ET NEW HAVEN, Conn., Dec. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced positive results from the human abuse potential (HAP) study of oral nalbuphine. ww
Corporate presentation will be held on Wednesday, December 4, 2024, at 1:00 p.m. ET NEW HAVEN, Conn., Nov. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that Jennifer Good, President and Chief Executive Officer, will be presenting at the Piper Sandler 36th Annual Healthcare Conference on Wednesday, December 4, at 1:00p.m. ET. Held from December 3-5 in New York, Ms. Good and Ms. Delfini, Chief Financial Officer, will also part
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Oct. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2024. www.trevithe
Topline results are expected in the first quarter of 2025 NEW HAVEN, Conn., Oct. 21, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that it has completed enrollment in its Phase 2a trial for the treatment of RCC ("RIVER") and expects to report topline data in the first quarter of 2025. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc
NEW HAVEN, Conn., Oct. 15, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending the following investor and medical conferences in October and November. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)">
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
4 - Trevi Therapeutics, Inc. (0001563880) (Issuer)
NEW HAVEN, Conn., Sept. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of James V. Cassella, Ph.D., as Chief Development Officer (CDO). www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)" alt="Trevi Therapeutics, Inc. www.trevitherapeutics.com (PRNewsfoto/Trevi Therapeutics, Inc.)"> "I am delighte
Margaret Garin, MD, MSCR, joins team to advance the development of Haduvio in chronic cough indications NEW HAVEN, Conn., April 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced the appointment of Margaret Garin, MD, MSCR, as Vice President of Clinical Development. Dr. Garin will be responsible for progressing the clinical development of Haduvio in chronic cough and brings unique and relevant experience from her previous lead role in clinical d
David Clark, MD, MRCP, will lead the continued development of Haduvio™ NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.
NEW HAVEN, Conn., Aug. 9, 2021 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of Lisa Delfini, CPA, as Chief Financial Officer and Danine Summers, as Vice President, Medical Affairs. Ms. Delfini will lead the accounting and finance operations. Ms. Summers will be responsible for educating the medical community on Haduvio's data and development programs through publications, congresses and relationship building with key opinion leaders.
Industry Veteran to Lead the Clinical Development of Haduvio™ in Multiple Indications NEW HAVEN, Conn., Feb. 01, 2021 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced the appointment of William Forbes, Pharm.D., as Chief Development Officer. Dr. Forbes will join Trevi’s senior management team and be responsible for leading the clinical development of Haduvio which is in late-stage clinical trials in its two lead indications. “I am happy to welcome Bill to our executive leadership team,” sai
H.C. Wainwright reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $7.50 from $6.00 previously
Leerink Partners resumed coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $7.00 from $6.00 previously
H.C. Wainwright initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $6.00
Raymond James initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $9.00
Rodman & Renshaw initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $7.00
B. Riley Securities initiated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $6.00
SVB Leerink initiated coverage of Trevi Therapeutics with a rating of Outperform and set a new price target of $6.00
Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $8.00 from $10.00 previously
Needham reiterated coverage of Trevi Therapeutics with a rating of Buy and set a new price target of $10.00 from $12.00 previously
Statistically significant lower "Drug Liking" for the 81mg and 162mg doses of oral nalbuphine vs. butorphanol covering our clinical dose range Company to host a conference call and webcast today at 5:00 p.m. ET NEW HAVEN, Conn., Dec. 3, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced positive results from the human abuse potential (HAP) study of oral nalbuphine. ww
Completed enrollment of the Phase 2a RIVER trial in refractory chronic cough (RCC) with topline results expected in the first quarter of 2025 Reached 50% enrollment for the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF), with sample size re-estimation outcome expected in December 2024 Ended the third quarter of 2024 with $65.5 million in cash, cash equivalents and marketable securities, with expected cash runway into the second half of 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Nov. 6, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investig
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Oct. 30, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, November 6, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended September 30, 2024. www.trevithe
Topline results expected in the fourth quarter of 2024 in the Phase 2a RIVER trial in refractory chronic cough (RCC) Sample size re-estimation milestone is expected in the fourth quarter of 2024 in the Phase 2b CORAL trial in chronic cough in idiopathic pulmonary fibrosis (IPF) Ended the second quarter of 2024 with $69.5 million in cash, cash equivalents and marketable securities with expected cash runway into 2026 Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 8, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the tr
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., Aug. 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Thursday, August 8, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended June 30, 2024. www.trevitherapeutics.
Reaffirms guidance for the Phase 2a RIVER trial in refractory chronic cough and Human Abuse Potential (HAP) Study with topline data for each expected in the second half of 2024 Topline results continue to be expected in the first half of 2025 for the Phase 2b CORAL trial in chronic cough in IPF IND cleared with the FDA for planned Phase 1b trial to evaluate respiratory physiology in IPF patients with varying disease severity Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., May 7, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER)
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., May 1, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Tuesday, May 7, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter ended March 31, 2024. www.trevitherapeutics.com
Reaffirms guidance for the Phase 2a RIVER trial of Haduvio in RCC patients with topline data expected in the second half of 2024 Enrollment progressing in the Phase 2b CORAL dose-ranging trial of Haduvio for the treatment of chronic cough in IPF patients Human Abuse Potential Study more than 50% enrolled Management to host a conference call and webcast today at 4:30 p.m. ET NEW HAVEN, Conn., March 20, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today an
Conference call and webcast to be held at 4:30 p.m. ET NEW HAVEN, Conn., March 13, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for patients with chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will host a conference call and live audio webcast on Wednesday, March 20, 2024, at 4:30 p.m. ET, to provide a corporate update and review the Company's financial results for the quarter and year ended December 31, 2023. www.trevi
Plans to initiate three clinical studies in chronic cough indications for later this year remain on track Data from Phase 2 CANAL trial of chronic cough in patients with idiopathic pulmonary fibrosis published in NEJM Evidence Management to host a conference call and webcast today at 4:30 p.m. EDT NEW HAVEN, Conn., Aug. 10, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (NASDAQ:TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced financial results for the quarter ende